

Review Article

Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades

Grytten N, Torkildsen Ø, Myhr K-M. Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. Acta Neurol Scand 2015; 132 (Suppl. 199): 29–36.

© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Norway has been subjected to numerous epidemiological investigations on the prevalence and incidence of multiple sclerosis (MS), dating back to 1935. The objective of this study was to review the studies on the prevalence and incidence of MS in Norway, provide an update on the prevalence of MS in Norway, and describe the time trends in the prevalence and incidence of MS in relation to risk factors, case ascertainment, and data. We performed a systematic search on PubMed and MEDLINE up to November 2014 using the search string ‘multiple sclerosis prevalence in Norway’ or ‘multiple sclerosis incidence in Norway’. In addition, we scrutinized the reference lists of the publications identified for relevant citations. We retrieved data on the distribution of MS in Norway on December 31, 2013 from the Norwegian Multiple Sclerosis Registry and Biobank and the Norwegian Patient Registry. We identified 29 articles. From 1961 to 2014, the reported prevalence of MS increased from 20 to 203 per 100,000 inhabitants, and the incidence increased from 1.9 to 8.0 per 100,000. The nationwide crude prevalence in Norway, based on the Norwegian Patient Registry, was 208 per 100,000 on December 31, 2013. The reported prevalence of MS in Norway has increased 10-fold, with several possible causes. During eight decades, neurological health services have generally become more accessible to the population, and transforming diagnostic criteria has made the diagnosis of MS more precise and valid. There have also been changes in lifestyle behavior and known risk factors, such as vitamin D and smoking, that might have contributed to the increased incidence of MS. A possible role of increased survival in MS needs to be examined further.

**N. Grytten^{1,2}, Ø. Torkildsen^{1,2},
K.-M. Myhr^{1,3}**

¹KG Jepsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Bergen, Norway; ²Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway; ³Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway

This article is commented on by Berg-Hansen et al, published in 132: 364–367 (DOI: 10.1111/ane.12489).

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Key words: multiple sclerosis; incidence; prevalence; time trends; environmental risk factors

N. Grytten, Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, N-5021 Bergen, Norway
Tel.: +47 55975503
Fax: +47 55975901
e-mail: nina.grytten@helse-bergen.no

Accepted for publication April 10, 2015

Introduction

The prevalence and incidence of multiple sclerosis (MS) have frequently been reported from different regions of Norway, and the first studies were based on data eight decades ago. Norway is located up to 71°N and is the northernmost country with a substantial population of people with a high risk of MS (1). Norway also has one of the most developed and equitable healthcare

systems in the world and has several national registries to monitor different aspects of health.

Based on data dating back to 1935–1948, the distribution of MS in Norway was described by Swank et al. (2) in 1951, postulating a latitude gradient between a high-risk area of MS in the eastern inland and a low-risk area at the western coast. Subsequent studies confirmed an uneven distribution of MS in Norway. These early investigations gave rise to the hypothesis of a latitude gradient of MS in Norway and possible environmental factors in MS causation (3, 4). Several publications have

since reported an increased prevalence and incidence of MS in Norway, and the most recent nationwide publication (5) concluded that the MS prevalence in Norway is among the highest reported worldwide and that there is no longer any evidence of a latitude gradient.

MS prevalence and incidence studies in Norway span eight decades and should be reviewed in light of the data sources, which have evolved from questionnaires in the previous studies to patient records at the hospital and to data obtained from public registries in recent publications. Healthcare services have become more available to and universal for all residents of Norway, including such diagnostic innovations as cerebrospinal fluid examinations, evoked potentials and magnetic resonance imaging (MRI), made available to people with MS in Norway from 1986. Similarly, the diagnostic criteria for MS have evolved from early clinically based criteria (6, 7) to MRI-based criteria (8), currently revised (9), and case ascertainment has improved dramatically. The recent immigration to Norway from countries with lower MS prevalence is also affecting the prevalence and risk of disease in Norway (10), and improved survival in the general population and among people with MS can at least partly explain the recent increase in the prevalence of MS (11). This article reviews the studies on the prevalence and incidence of MS in Norway, provides an update on the prevalence of MS in Norway, and describes the time trends in the prevalence and incidence of MS in relation to risk factors and case ascertainment.

Methods

We searched PubMed and MEDLINE on November 15, 2014 using the search string ‘multiple sclerosis prevalence in Norway’ or ‘multiple sclerosis incidence in Norway’. In addition, we scrutinized the reference lists of the publications identified for relevant citations. Furthermore, we retrieved data on people with MS from the Norwegian Multiple Sclerosis Registry and Biobank and from the Norwegian Patient Registry on December 31, 2013 to calculate updated figures for the prevalence of MS in Norway.

Results

Prevalence and incidence studies in Norway

1935–1961 – In 1952, Swank et al. (2) published the first nationwide study on the incidence of MS in Norway during 1935–1948. Based on a survey of doctors at hospitals and neurologists in Norway,

they found 1106 people with MS and a mean annual incidence of MS of 2.7 per 100,000 inhabitants. An uneven distribution of MS was detected, with the highest incidence in the inland areas and the lowest incidence in southern rural Norway, where most people lived from farming and dairying. Based on their findings, Swank et al. suggested that differences in diet could be the main cause of the uneven distribution of MS in Norway. Specifically, they suggested that a high intake of fish, such as that in the coastal areas, could offer protection against MS, whereas a diet with a high intake of dairy and other animal products, typically found in the inland areas, could increase the risk of MS.

Westlund carried out the second study on the distribution of MS in 1951–1966 in Norway in two publications (3, 4) based on the incidence calculated using disability pension and mortality data. Westlund confirmed the risk zone of MS in Norway, with a low-risk area in the north and west and a high-risk area in the central inland and in the south (Fig. 1 shows the geography in Norway). The first studies on the distribution of MS eight decades ago, which found a latitude gradient of high incidence of MS in southern and eastern Norway and a low incidence in the north and along the western coast, supported the hypothesis of MS risk factors in environment and lifestyle, especially diet, which is still a promising candidate in explaining how MS is caused today.

1961–1991 – Fig. 2A,B illustrates the time trends in the prevalence and incidence of MS in Norway




Figure 1. Counties in Norway.

Time trends in incidence and prevalence of MS in Norway

from 1961 to 2014. The first MS prevalence study in Norway was carried out in Møre and Romsdal in northwestern Norway and reported a prevalence of 24 per 100,000 on January 1, 1961 (12). The study by Presthus (12) also reported a mean annual incidence rate of 1.9 per 100,000 inhabitants during 1920–1960. In Hordaland, also in coastal northwestern Norway, the mean annual incidence of MS was 2.5 per 100,000 population in 1958–1962 and the prevalence was 20 per 100,000 population on January 1, 1963 (13). The prevalence in Hordaland in 1963–1982 was also clustered and lower in the coastal area than in the inland area (14).

In Vestfold County, southeastern Norway, the incidence was 5.5 during 1958–1962 and the prevalence of 62 per 100,000 population in 1963, was threefold higher than in Hordaland (15). In Troms and Finnmark, the northernmost counties in Norway, a lower incidence of 1.3 per 100,000 population was reported in 1968–1972 and a prevalence of 21 per 100,000 population was reported on January 1, 1973 (16). The second

investigation from Troms and Finnmark showed a slight increase in incidence, 1.9 per 100,000 population in 1974–1982, and an increased prevalence of 32 per 100,000 population on January 1, 1983 (17). By 1983, the prevalence in Hordaland increased almost threefold compared with the 1963 study to 60 per 100,000 population, and the incidence was 6.7 per 100,000 population (18). The subsequent study from Vestfold reported a decreased incidence to 4.5 per 100,000 population during 1978–1982, but an increased prevalence of 86 per 100,000 in 1983 (19). Although follow-up studies demonstrated that the incidence and prevalence were increasing, the reports from Vestfold showed that the distribution of MS could fluctuate over time, possibly influenced by environmental risk factors. The third follow-up study in Møre and Romsdal reported an increased incidence of 5.7 per 100,000 population in 1980–1984 (20) and a threefold increase in prevalence to 75 per 100,000 population in 1985 (21) compared with the 1961 study (12).




Figure 2. (A) Time trends in prevalence and diagnostic criteria of multiple sclerosis (MS) in Norway during 1961–2014, with 95% CI where available. The year on x-axis refers to the prevalence year and not the publication year of the study. (B) Time trends in incidence and diagnostic criteria of MS in Norway during 1961–2007, with 95% CI where available. The year on x-axis refers to the prevalence year and not the publication year of the study.

1991–2014 – The third study conducted in Troms and Finnmark (22) showed an increase in incidence to 4.3 per 100,000 population in 1989–1992 and more than a twofold increase in prevalence to 73 per 100,000 population in 1993. The first study from Oslo, the capital in eastern central Norway, reported an increase in incidence from 3.6 to 8.7 per 100,000 population in 1972–1996 and a prevalence of 120 per 100,000 population in 1995 (23). Nordland, in northern central Norway, had an incidence of 5.4 per 100,000 population in 1985–1989 and a prevalence of 106 per 100,000 population in 2000 (24). Similarly, in Nord-Trøndelag, in northern Norway, the incidence in 1984–1988 was 5.3 per 100,000 population but with a higher prevalence of 164 per 100,000 population in 2000 (25). Oppland, a rural inland county known for its high incidence already reported by Swank et al. (2), rose from 3.9 per 100,000 population in 1935–1948 to 6.5 in 1989–1993 to 7.4 in 1994–1998, and the prevalence was 174 per 100,000 population in 2002 (26). Although the study by Gronning et al. in 1991 (18) indicated that the incidence during the 1980s fluctuated, the third follow-up study from Hordaland during 50 years (27) found a stable incidence of 6 per 100,000 population since 1978 but a 2.5-fold increase in prevalence in 30 years to 151 per 100,000 population in 2003. In 1991, a study by Riise et al. (28) also found residential clustering of MS among people aged 13–20 years in Hordaland. The second Oslo study corroborated the results from the latest Hordaland study, reporting a yearly incidence of 6.6 per 100,000 during 2001–2005 and a prevalence of 148 per 100,000 in 2006 (29). For Vest-Agder, the southernmost county in Norway, known for its high incidence of 3.9 per 100,000 population in 1935–1948 (2), the only study since reported an incidence of 8.0 per 100,000 population during 2001–2006 and a prevalence of 180 per 100,000 population in 2007 (30). The latest report corroborating a trend toward increasing prevalence was reported from Oslo: 203 per 100,000 population in 2014 (5). The recent Oslo study no longer found any evidence for the latitude gradient in MS prevalence in Norway.

Studies on sex ratio

One nationwide study of the sex ratio in MS has been conducted in Norway (31). This study found an increase in the female-to-male ratio, from 1.7 among those born in 1930–1935 to 2.6 among those born in 1970–1979. The authors also noted that the sex ratio had no latitudinal gradient and

that the increasing sex ratio was strongly determined by people with relapsing–remitting onset.

Immigration studies in Norway

Genetic disposition and exposure to environmental risk factors during childhood causes immigrants to Norway to have a different risk of MS compared with ethnic Norwegians. In Norway, most immigrants settle in Oslo, and studies on how non-ethnic Norwegians affect the prevalence of MS have primarily focused on data from this region. The first study on the effect of immigration from countries with a low risk of MS to Norway was published in 2008 (29). The authors concluded that immigrants have an increased risk of MS after migrating to Norway, especially among those from the Middle East and Iran. In 2014, a follow-up study on immigration and prevalence was published, detecting a prevalence of 162 per 100,000 population among first-generation Iranian immigrants in Oslo vs the prevalence of 99 per 100,000 population in Iran (10). The study also found that first-generation immigrants from northern Europe had a prevalence of MS close to the Norwegian prevalence of 203 per 100,000, whereas the immigrants from Africa and Asia had a much lower prevalence of MS of 71 per 100,000. The non-European people with MS were 9.5 years younger than the Europeans with MS, and among second-generation Pakistani, the prevalence was close to the prevalence among the ethnic Norwegian population, whereas the prevalence among first-generation Pakistani was the lowest among all immigrant groups in Oslo. Thus, the Pakistani suffered a threefold increase in the risk of MS during one generation (10). Increased disease severity and younger age at onset were also detected among non-Western immigrants with MS, as measured by the Multiple Sclerosis Severity Score (32).

Updated prevalence of MS in Norway until 2014

Two review studies have evaluated the prevalence of MS in Norway, based on available prevalence data, and estimated a nationwide prevalence of 150 per 100,000 population in the south and 100 per 100,000 population in the north in 2006 (33) and 165 per 100,000 population in 2012 (34). The first nationwide study on prevalence in Norway reported a crude prevalence of 203 per 100,000 population on January 1, 2012 (5). The nationwide prevalence study data were based on data from five health regions; north, middle, west, and south, retrieved from the Norwegian Multiple Sclerosis

Registry and Biobank, the Oslo Multiple Sclerosis Registry and the Norwegian Patient Registry, the Norwegian Prescription Database and Statistics Norway. The authors concluded that the prevalence in Norway is among the highest ever reported and that there was no longer evidence of a latitude gradient, as was found in the previous works on incidence by Swank et al. (2) and Westlund (4).

To follow up on the nationwide prevalence of MS in Norway and to estimate the prevalence in the counties, we retrieved data from the Norwegian Multiple Sclerosis Registry and Biobank and the Norwegian Patient Registry. The Norwegian Patient Registry data included unique patients who were hospitalized, seen at an outpatient clinic or by a neurologist in private practice during 2011–2013. The numbers were not adjusted, neither reduced for deaths, nor increased for those who were not treated during the period. The crude prevalence in Norway on December 31, 2013 was estimated to be 208 per 100,000 (Table 1). The prevalence seemed to peak in Møre and Romsdal, northwestern Norway, at 275 per 100,000, being the highest ever reported in Norway. Oppland, described as a high-risk area of MS already in 1935 (2), still had a high prevalence of 250 per 100,000 population. Compared with the 2012 report on prevalence (5), our recent data reveal an even higher prevalence of MS, but confirm no evidence of a latitudinal gradient.

Table 1 Prevalence of multiple sclerosis (MS) in Norway by county, December 31, 2013

County or counties ^a	Population	MS prevalence (per 100,000 population)	Estimated number of people with MS
Troms and Finnmark	237,257	207	490
Nordland	240,877	190	457
Nord-Trøndelag	135,142	225	304
Sør-Trøndelag	306,197	242	740
Møre & Romsdal	261,530	275	718
Sogn & Fjordane	108,965	242	264
Hordaland	505,246	210	1,060
Rogaland	459,625	176	809
Vest-Agder and Aust-Agder	292,225	230	673
Telemark	171,469	206	353
Vestfold	240,860	196	473
Buskerud	272,228	229	624
Oslo	634,463	209	1,327
Akershus	575,757	142	820
Oppland and Hedmark	382,253	250	956
Østfold	284,962	201	572
Norway	5,109,056	208	10,628

^aTroms and Finnmark, Vest-Agder and Aust-Agder, Oppland and Hedmark are combined.

Discussion

Norway is a high-risk area for MS, with one of the highest prevalence rates ever reported. In contrast to evidence for a latitude gradient in the neighboring countries (35, 36), the latest nationwide reports from Norway show no latitude gradient, as postulated by Swank et al. in their pioneering work 1952 (2, 4). This could be caused by conformity in lifestyle and nutrition and by the fact that people are now being exposed to similar risk factors independent of geographical residence.

The northernmost counties of Troms and Finnmark have evolved from a low-risk area to a high-risk area for MS during the past 50 years. The population in the north is still an admixture of the Sami population, which has a more favorable genetic risk profile for developing MS (37). The unchanged population of Troms and Finnmark indicates that the previous reports might have underestimated the prevalence and that the increased prevalence could be due to more complete case ascertainment. The increasing prevalence and incidence found in Møre and Romsdal and in Troms and Finnmark could also signify a real increase related to environmental factors. Fluctuating incidence was reported in Vestfold parallel to increasing prevalence and may indicate temporal influence by environmental risk factors for developing the disease. However, the incidence was stable for 25 years since 1978 in Hordaland. The trend of increasing prevalence with stable incidence might reflect the impact of improved diagnostic methods, improved treatment, and prolonged survival.

The studies were based on variable diagnostic criteria; at first the clinically based Allison & Millar criteria from 1954 (38), followed by the McAlpine criteria from 1961 (7), the Rose et al. criteria from 1976 (39), the Poser criteria in 1983 that included evoked potentials (paraclinical) and cerebrospinal fluid (laboratory) support for the diagnosis (6), and finally replaced by the McDonald's criteria from 2001 (40) with subsequent revisions in 2005 (8) and in 2011 (9), introducing use of magnetic resonance imaging for early diagnosis. Fig. 2A illustrates the changes in diagnostic criteria used in the studies of MS prevalence in Norway. During 50 years of follow-up on the prevalence and incidence of MS in Hordaland, the time from onset to diagnosis decreased from a mean time of 10 years to <1 year by 2003 (27). Active use of magnetic resonance imaging findings in the diagnostic evaluation has revolutionized the ability to make an early diagnosis (40). With the year of onset

approach used in most MS studies, the McDonald's diagnostic criteria may cause a catch-up effect (by the use of magnetic resonance imaging) on prevalence and incidence retrospectively. This might result in a peak of case ascertainment, causing a temporal overestimated steep increase in prevalence. Future studies will show whether this catch-up effect is occurring or whether further increase will appear. In addition, both general increased survival in the population and improved treatment of people with MS might account for the increase in MS prevalence despite an apparently stabilizing incidence. A possible role of increased survival in MS due to disease-modifying treatments needs to be examined further (11).

Change in environmental risk factors for MS, such as lifestyles and vitamin D-avoiding habits, such as use of sunscreen and less frequent fatty fish consumption could also account for an increased prevalence of MS (41–43). Kampman et al. (43) reported that increased outdoor activity during summer in childhood, and that consumption of fish, both being sources of vitamin D, are associated with a decreased risk of MS, the latter being confirmed in a recent study (44). This could point to environmental interaction between diet, latitude, and the risk of MS. Corroborating these findings, Bjørnevik et al. (41) detected a significant association between infrequent summer outdoor activity and the risk of MS in Norway between 16 and 18 years. Cortese et al. (45) have also suggested the importance of vitamin D in early life, showing that intake of cod liver oil during adolescence may reduce the risk of developing MS in Norway. In contrast, the increasing frequency of overweight among young people, also in Scandinavian populations, seems to increase the MS risk (46–48). Epstein-Barr virus is another important immunogenetic factor causing MS (49–51). The complexity is further illustrated by smoking that increases the risk of MS (52–54). The frequency of smoking in Norway has been decreasing, but no effects on MS incidence have yet been detected.

To account for the similarity in prevalence between Norway and the neighboring countries, it has been suggested that a plateau of prevalence has been reached, adding the sufficient genetic and environmental MS risk factors (1). As Kampman & Brustad demonstrated in their study in 2008, many people in the northernmost counties in Norway enrich their diet with vitamin D to compensate for ambient vitamin D insufficiency for large parts of the year (42). This behavioral and cultural adaptation to the

environment could possibly explain why the latitude gradient is lacking in Norway, in contrast to Sweden (35).

Conclusion

The prevalence of MS in Norway has increased 10-fold during the past five decades, the female–male sex ratio has increased, and second-generation immigrants have an increased risk of MS compared with native populations in their countries of origin. Altogether, these findings indicate that environmental risk factors strongly affect disease susceptibility. Early adolescence seems to be an important susceptibility period, and vitamin D supplementation might reduce the risk of developing MS.

Acknowledgments

None.

Conflict of interest

ØT has participated on a scientific advisory board for Biogen Idec and received speaker honoraria and travel grants from Genzyme, Merck-Serono, Novartis, and Biogen Idec. KMM has received speaker honoraria, travel support, and/or unrestricted research grants from Almirall, Allergan, Bayer Pharma, Biogen Idec, Genzyme, Sanofi Aventis, Novartis, and Merck Serono.

References

1. SIMPSON JR S, TAYLOR BV. The Scandinavian paradox revisited: editorial comment on Berg-Hansen et al. 'High prevalence and no latitude gradient of multiple sclerosis in Norway'. *Mult Scler* 2014;**20**:1675–7.
2. SWANK RL, LERSTAD O, STROM A, BACKER J. Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. *N Engl J Med* 1952;**246**:722–8.
3. WESTLUND K. Recent statistical data on multiple sclerosis and some other diseases in Norway. *Nordic Council Arctic Med Res Rep* 1982;**32**:19–29.
4. WESTLUND K. Distribution and mortality time trend of multiple sclerosis and some other diseases in Norway. *Acta Neurol Scand* 1970;**46**:455–83.
5. BERG-HANSEN P, MOEN S, HARBO H, CELIUS E. High prevalence and no latitude gradient of multiple sclerosis in Norway. *Mult Scler* 2014;**20**:1780–2.
6. POSER CM, PATY DW, SCHEINBERG L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. *Ann Neurol* 1983;**13**:227–31.
7. MCALPINE D. The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. *Brain* 1961;**84**:186–203.
8. POLMAN CH, REINGOLD SC, EDAN G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". *Ann Neurol* 2005;**58**:840–6.

9. POLMAN CH, REINGOLD SC, BANWELL B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol* 2011;**69**:292–302.
10. BERG-HANSEN P, MOEN SM, SANDVIK L et al. Prevalence of multiple sclerosis among immigrants in Norway. *Mult Scler* 2014; DOI: 10.1177/1352458514554055.
11. GRYTEN TORKILDSEN N, LIE SA, AARSETH JH, NYLAND H, MYHR KM. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. *Mult Scler* 2008;**14**:1191–8.
12. PRESTHUS J. Multiple sclerosis in More og Romsdal County, Norway. *Acta Neurol Scand* 1966;**42**(Suppl 19):2–8.
13. LARSEN JP, AARLI JA, NYLAND H, RIISE T. Western Norway, a high-risk area for multiple sclerosis: a prevalence/incidence study in the county of Hordaland. *Neurology* 1984;**34**:1202–7.
14. LARSEN JP, RIISE T, NYLAND H, KVALE G, AARLI JA. Clustering of multiple sclerosis in the county of Hordaland, Western Norway. *Acta Neurol Scand* 1985;**71**:390–5.
15. OFTEDAL SI. Multiple sclerosis in vestfold county. *Acta Neurol Scand Suppl* 1965;**16**:1–62.
16. DE GRAAF AS. Multiple sclerosis in northern Norway. *Eur Neurol* 1974;**11**:281–95.
17. GRONNING M, MELLGREN SI. Multiple sclerosis in the two northernmost counties of Norway. *Acta Neurol Scand* 1985;**72**:321–7.
18. GRONNING M, RIISE T, KVALE G, NYLAND H, LARSEN JP, AARLI JA. Incidence of multiple sclerosis in Hordaland, western Norway: a fluctuating pattern. *Neuroepidemiology* 1991;**10**:53–61.
19. EDLAND A, NYLAND H, RIISE T, LARSEN JP. Epidemiology of multiple sclerosis in the county of Vestfold, eastern Norway: incidence and prevalence calculations. *Acta Neurol Scand* 1996;**93**:104–9.
20. MIDGARD R, RIISE T, SVANES C, KVALE G, NYLAND H. Incidence of multiple sclerosis in More and Romsdal, Norway from 1950 to 1991. An age-period-cohort analysis. *Brain* 1996;**1**:203–11.
21. MIDGARD R, RIISE T, NYLAND H. Epidemiologic trends in multiple sclerosis in More and Romsdal, Norway: a prevalence/incidence study in a stable population. *Neurology* 1991;**41**:887–92.
22. GRONLIE SA, MYRVOLL E, HANSEN G, GRONNING M, MELLGREN SI. Multiple sclerosis in North Norway, and first appearance in an indigenous population. *J Neurol* 2000;**247**:129–33.
23. CELIUS EG, VANDVIK B. Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period. *Eur J Neurol* 2001;**8**:463–9.
24. ALSTADHAUG KB, OLAVSEN J, SALVESEN R. Occurrence of multiple sclerosis in Nordland, 1970–1999. *Tidsskrift for den Norske laegeforening: Tidsskrift for praktisk medicin, ny raekke* 2005;**125**:431–3.
25. DAHL OP, AARSETH JH, MYHR KM, NYLAND H, MIDGARD R. Multiple sclerosis in Nord-Trøndelag County, Norway: a prevalence and incidence study. *Acta Neurol Scand* 2004;**109**:378–84.
26. RISBERG G, AARSETH JH, NYLAND H, LAUER K, MYHR KM, MIDGARD R. Prevalence and incidence of multiple sclerosis in Oppland County: a cross-sectional population-based study in a landlocked county of Eastern Norway. *Acta Neurol Scand* 2011;**124**:250–7.
27. GRYTEN N, GLAD SB, AARSETH JH, NYLAND H, MIDGARD R, MYHR KM. A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. *Neurology* 2006;**66**:182–6.
28. RIISE T, GRONNING M, KLAUBER MR, BARRETT-CONNOR E, NYLAND H, ALBREKTSSEN G. Clustering of residence of multiple sclerosis patients at age 13 to 20 years in Hordaland, Norway. *Am J Epidemiol* 1991;**133**:932–9.
29. SMESTAD C, SANDVIK L, HOLMOY T, HARBO HF, CELIUS EG. Marked differences in prevalence of multiple sclerosis between ethnic groups in Oslo, Norway. *J Neurol* 2008;**255**:49–55.
30. VATNE A, MYGLAND A, LJOSTAD U. Multiple sclerosis in Vest-Agder County, Norway. *Acta Neurol Scand* 2011;**123**:396–9.
31. KAMPMAN MT, AARSETH JH, GRYTEN N et al. Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway. *J Neurol* 2013;**260**:1481–8.
32. BERG-HANSEN P, SMESTAD C, SANDVIK L, HARBO HF, CELIUS EG. Increased disease severity in non-Western immigrants with multiple sclerosis in Oslo, Norway. *Eur J Neurol* 2013;**20**:1546–52.
33. TORKILDSEN O, GRYTEN N, MYHR KM. Immunomodulatory treatment of multiple sclerosis in Norway. *Acta Neurol Scand Suppl* 2007;**187**:46–50.
34. MIDGARD R. Incidence and prevalence of multiple sclerosis in Norway. *Acta Neurol Scand* 2012;**126** (Suppl. 195): 36–42.
35. AHLGREN C, ODEN A, LYCKE J. High nationwide prevalence of multiple sclerosis in Sweden. *Mult Scler* 2011;**17**:901–8.
36. BENTZEN J, FLACHS EM, STENAGER E, BRONNUM-HANSEN H, KOCH-HENRIKSEN N. Prevalence of multiple sclerosis in Denmark 1950–2005. *Mult Scler* 2010;**16**:520–5.
37. HARBO HF, UTSI E, LORENTZEN AR et al. Low frequency of the disease-associated DRB1*15-DQB1*06 haplotype may contribute to the low prevalence of multiple sclerosis in Sami. *Tissue Antigens* 2007;**69**:299–304.
38. ALLISON RS, MILLAR JH. Prevalence of disseminated sclerosis in Northern Ireland. *Ulster Med J* 1954;**23**:1–27.
39. ROSE AS, ELLISON GW, MYERS LW, TOURTELLOTTE WW. Criteria for the clinical diagnosis of multiple sclerosis. *Neurology* 1976;**26**:20–2.
40. McDONALD WI, COMPSTON A, EDAN G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. *Ann Neurol* 2001;**50**:121–7.
41. BJORNEVIK K, RIISE T, CASETTA I et al. Sun exposure and multiple sclerosis risk in Norway and Italy: the EnvIMS study. *Mult Scler* 2014;**20**:1042–9.
42. KAMPMAN MT, BRUSTAD M. Vitamin D: a candidate for the environmental effect in multiple sclerosis – observations from Norway. *Neuroepidemiology* 2008;**30**:140–6.
43. KAMPMAN MT, WILSGAARD T, MELLGREN SI. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. *J Neurol* 2007;**254**: 471–7.
44. BAARNHIELM M, OLSSON T, ALFREDSSON L. Fatty fish intake is associated with decreased occurrence of multiple sclerosis. *Mult Scler* 2014;**20**:726–32.
45. CORTESI M, BJORNEVIK K, HOMØY T et al. Timing of cod liver oil use as a vitamin D source and multiple sclerosis risk in Norway. The EnvIMS Study. *Mult Scler J* 2014;**20** (S1):214–5.
46. WESNES K, RIISE T, CASETTA I et al. Body size and the risk of multiple sclerosis in Norway and Italy: the EnvIMS study. *Mult Scler* 2015;**21**:388–95.
47. HEDSTROM AK, OLSSON T, ALFREDSSON L. High body mass index before age 20 is associated with increased risk

- for multiple sclerosis in both men and women. *Mult Scler* 2012;**18**:1334–6.
48. MUNGER KL, CHITNIS T, ASCHERIO A. Body size and risk of MS in two cohorts of US women. *Neurology* 2009;**73**:1543–50.
 49. JONS D, SUNDSTROM P, ANDERSEN O. Targeting Epstein–Barr virus infection as an intervention against multiple sclerosis. *Acta Neurol Scand* 2015;**131**:69–79.
 50. SIMPSON S Jr, TAYLOR B, BURROWS J et al. EBV & HHV6 reactivation is infrequent and not associated with MS clinical course. *Acta Neurol Scand* 2014;**130**:328–37.
 51. KVISTAD S, MYHR KM, HOLMOY T et al. Antibodies to Epstein–Barr virus and MRI disease activity in multiple sclerosis. *Mult Scler* 2014;**20**:1833–40.
 52. RIISE T, NORTVEDT MW, ASCHERIO A. Smoking is a risk factor for multiple sclerosis. *Neurology* 2003;**61**:1122–4.
 53. GUSTAVSEN MW, PAGE CM, MOEN SM et al. Environmental exposures and the risk of multiple sclerosis investigated in a Norwegian case-control study. *BMC Neurol* 2014;**14**:196.
 54. SALZER J, HALLMANS G, NYSTROM M, STENLUND H, WADDELL G, SUNDSTROM P. Smoking as a risk factor for multiple sclerosis. *Mult Scler* 2013;**19**:1022–7.